Weill Cornell Sandra & Edward Meyer Cancer Center | Strategic Alliance Partners

Latest from Weill Cornell Sandra & Edward Meyer Cancer Center


Tagawa Takes Stock of Future of Sacituzumab Govitecan in Urothelial Carcinoma

August 16, 2021

Sacituzumab govitecan-hziy, a Trop-2directed antibody-drug conjugate with an SN-38 payload, has carved out a role in the treatment landscape for patients with locally advanced or metastatic urothelial cancer following accelerated approval by the FDA.

The Chance to Make a Difference Made Herbst a Lung Cancer Pioneer

May 18, 2021

Roy S. Herbst, MD, PhD, was inspired to become an oncologist during his first week as an MD/PhD candidate at Cornell University and The Rockefeller University, thanks in part to Ralph L. Nachman, MD, longtime chair of Weill Department of Medicine at Weill Cornell Medical College.